Global fund for the treatment of senile dementia
Collection "The Global Fund to discover senile dementia disease,"
which is the first high-risk fund allocated to finance new ways to
prevent and treat Alzheimer's disease, more than $ 100 million in
support of the British government and a number of leading pharmaceutical
companies in the world.
The Fund is unique in focusing on the difficulties faced by the treatment of this disease, as well as a combination of relevant government agencies and the pharmaceutical industry that. Among the pharmaceutical companies participating in the Fund GlaxoSmithKline and Johnson & Johnson and Eli Lilly and Pfizer and Biogen.
The initiative, announced by Health Minister Jeremy Hunt, the British, during a meeting in Geneva on Tuesday, after a conference of the Member States of the Group of Eight held in London in December / December 2013, which set a goal is to find an effective treatment for Alzheimer's disease and other diseases related to dementia no later than 2025.
Said Patrick Valence director of research and development company Glaxo Smith Kline Department, said that the 2025 goal "very ambitious" but the collection of financial resources through the new fund to support promising ideas from academic groups and small biotechnology companies, will help accelerate the pace of research.
The British government, which has worked with JP Foundation Morgan Financial Advisors in the establishment of the Fund, that "the door is open to new investors interested in the project to participate in the later stages of it."
As the leader of the project the British government contributed $ 22 million, and participated Glaxo Smith Kline $ 25 million, and Johnson & Johnson with ten million dollars, while other companies in financing the project contributed.The International Campaign for Alzheimer's disease, non-profit, that Alzheimer's disease is the most common -walzheimer Sourh- affects nearly 50 million people in the world has the figure of up to 135 million in 2050.
The Fund is unique in focusing on the difficulties faced by the treatment of this disease, as well as a combination of relevant government agencies and the pharmaceutical industry that. Among the pharmaceutical companies participating in the Fund GlaxoSmithKline and Johnson & Johnson and Eli Lilly and Pfizer and Biogen.
The initiative, announced by Health Minister Jeremy Hunt, the British, during a meeting in Geneva on Tuesday, after a conference of the Member States of the Group of Eight held in London in December / December 2013, which set a goal is to find an effective treatment for Alzheimer's disease and other diseases related to dementia no later than 2025.
Said Patrick Valence director of research and development company Glaxo Smith Kline Department, said that the 2025 goal "very ambitious" but the collection of financial resources through the new fund to support promising ideas from academic groups and small biotechnology companies, will help accelerate the pace of research.
The British government, which has worked with JP Foundation Morgan Financial Advisors in the establishment of the Fund, that "the door is open to new investors interested in the project to participate in the later stages of it."
As the leader of the project the British government contributed $ 22 million, and participated Glaxo Smith Kline $ 25 million, and Johnson & Johnson with ten million dollars, while other companies in financing the project contributed.The International Campaign for Alzheimer's disease, non-profit, that Alzheimer's disease is the most common -walzheimer Sourh- affects nearly 50 million people in the world has the figure of up to 135 million in 2050.
0 التعليقات:
إرسال تعليق